| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 03 Nov 2026 | 10-Q |
| 03 Nov 2026 |
8-K: Results of Operations and Financial Condition
SOUTH SAN FRANCISCO, Calif. – November 3, 2026 – Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the third quarter ended September 30, 2026, and provided business highlights. |
| 09 Sep 2026 |
Form 4: Chin Peter Scott, Chief Medical Officer
Sold 1,654 shares ($36.9K) |
| 04 Sep 2026 | 144 |
| 04 Sep 2026 |
Form 4: Thornberry Nancy, Director
Sold 11,439 shares ($262K) |
| 03 Sep 2026 |
Form 4: Schuth Alexander O., COFO and Secretary
Sold 2,768 shares ($64.9K) |
| 02 Sep 2026 | 144 |
| 01 Sep 2026 | 144 |
| 14 Aug 2026 |
Form 4: Watts Ryan J., Director
Gave 32,220 shares as a gift |
| 13 Aug 2026 |
Form 4: Schuth Alexander O., COFO and Secretary
Sold 2,857 shares ($71.6K) |
| 11 Aug 2026 | 144 |
| 06 Aug 2026 | 10-Q |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
SOUTH SAN FRANCISCO, Calif. – August 6, 2026 – Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the second quarter ended June 30, 2026, and provided business highlights. |
| 04 Aug 2026 | SCHEDULE 13G/A |
| 28 Jul 2026 |
8-K: Completion of Acquisition or Disposition of Assets
On July 27, 2026, Denali Therapeutics Inc. (the “Company”) completed the previously disclosed sale (the “Sale”) of its Rare Pediatric Disease Priority Review Voucher (the “PRV”) to a large pharmaceutical company. The Company received the... |
| 08 Jul 2026 | SCHEDULE 13G/A |
| 18 Jun 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
SOUTH SAN FRANCISCO, Calif., – June 18, 2026 – Denali Therapeutics Inc. (Nasdaq: DNLI) today announced it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $195... |
| 05 Jun 2026 |
Form 4: Flatley Jay T, Director
Received 6,408 shares as a grant or award · Granted 19,226 Stock Option (right to buy) |
| 05 Jun 2026 |
Form 4: Klein Peter S, Director
Received 6,408 shares as a grant or award · Granted 19,226 Stock Option (right to buy) |
Loading...